• 1
    Izuta S, Saneyoshi M, Sakurai T, Suzuki M, Kojima K, Yoshida S 1991 The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochem Biophys Res Commun 179: 776783.
  • 2
    Bazarbachi A, Nasr R, El-Sabban ME, Mahe A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de The H, Hermine O 2000 Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 14: 716721.
  • 3
    Falcone A, Lencioni M, Brunetti I, Pfanner E, Allegrini G, Antonuzzo A, Andreuccetti M, Malvaldi G, Danesi R, Del Tacca M, Conte PF 1997 Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 8: 539545.
  • 4
    Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Cummings FJ, Clark J, Browne MJ, Beitz J 1990 Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: A phase I study. J Natl Cancer Inst 82: 17101714.
  • 5
    Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, Calabresi P 1992 High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 70: 29292934.
  • 6
    Beitz JG, Darnowski JW, Cummings FJ, Browne M, Clark J, Bigley J, Weitberg A 1992 A Phase I and pharmacologic analysis of fluorouracil + leucovorin combined with infused high-dose zidovudine. Proc Am Assoc Cancer Res 33: 427.
  • 7
    Posner MR, Darnowski JW, Tessitore J, Bigley J, Parker LM, Stuart K, Huberman MA 1993 Phase I trial of high dose, intravenous zidovudine (AZT) and 5-fluoracil/leucovorin and cisplatin. Proc Am Assoc Cancer Res 12: 162.
  • 8
    Anand A, Ellis M, Tessitore J, Huberman M, Parker LM, Stuart K, Posner MRA 1995 Phase I study of intermittent high-dose zidovudine. 5-fluorouracil leucovirin and cisplatin. Proc Am Assoc Cancer Res 14: 481.
  • 9
    Furman PA, Barry DW 1988 Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med 85: 176181.
  • 10
    Multani AS, Furlong C, Pathak S 1998 Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. Int J Oncol 13: 923925.
  • 11
    Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, Agarwal RP, Xia W, Boise LH, Podack E, Harrington WJ Jr 1999 Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 59: 55145520.
  • 12
    Pressacco J, Erlichman C 1993 Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46: 19891997.
  • 13
    Melana SM, Holland JF, Pogo BG 1998 Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin Cancer Res 4: 693696.
  • 14
    Wang CA, Gaz RD 1985 Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149: 522527.
  • 15
    Shane E 2001 Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 86: 485493.
  • 16
    Falchetti A, Becherini L, Martineti V, Morelli A, Benvenuti S, Picariello L, Gennari L, Lampugnani R, Bordi C, Brandi ML 1999 Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma. Biochem Biophys Res Commun 265: 252255.
  • 17
    Velin AK, Herder A, Johansson KJ, Trulsson LM, Smeds S 2001 Telomerase is not activated in human hyperplastic and adenomatous parathyroid tissue. Eur J Endocrinol 145: 161164.
  • 18
    Kammori M, Nakamura K, Kanauchi H, Obara T, Kawahara M, Mimura Y, Kaminishi M, Takubo K 2002 Consistent decrease in telomere length in parathyroid tumors but alteration in telomerase activity limited to malignancies: Preliminary report. World J Surg 26: 10831087.
  • 19
    Kammori M, Nakamura K, Ogawa T, Mafune K, Tatutomi Y, Obara T, Onoda N, Fujiwara M, Izumiyama-Shimomura N, Mori M, Kaminishi M, Takubo K 2003 Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol (Oxf) 58: 4348.
  • 20
    Brandi ML, Fitzpatrick LA, Coon HG, Aurbach GD 1986 Bovine parathyroid cells: Cultures maintained for more than 140 population doublings. Proc Natl Acad Sci USA 83: 17091713.
  • 21
    Naasani I, Seimiya H, Tsuruo T 1998 Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 249: 391396.
  • 22
    Gan Y, Engelke KJ, Brown CA, Au JLS 2001 Telomere amount and length assay. Pharm Res 18: 16551659.
  • 23
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266: 20112015.
  • 24
    Soule HD, McGrath CM 1986 A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro Cell Dev Biol 22: 612.
  • 25
    Agarwal RP, Mian AM 1991 Thymidine and zidovudine metabolism in chronically Zidovudine-exposed cells in vitro. Biochem Pharmacol 42: 905911.
  • 26
    Törnevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S 1995 Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49: 829837.
  • 27
    Bridges EG, Faraj A, Sommadossi JP 1993 Inhibition of mammalian dna polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 45: 1571.
  • 28
    Dotzenrath C, Goretzki PE, Sarbia M, Cupisti K, Feldkamp J, Roher HD 2001 Parathyroid carcinoma: Problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 27: 383389.
  • 29
    Kebebew E 2001 Parathyroid carcinoma. Curr Treat Options Oncol 2: 347354.
  • 30
    Rasmuson T, Kristoffersson A, Boquist L 2000 Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma. Eur J Endocrinol 143: 749754.
  • 31
    Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A 1994 Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330: 757761.
  • 32
    Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A 1994 p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78: 13201324.
  • 33
    Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV 1996 Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 45: 195200.
  • 34
    Yoshimoto K, Endo H, Tsuyuguchi M, Tanaka C, Kimura T, Iwahana H, Kato G, Sano T, Itakura M 1998 Familial isolated primary hyperparathyroidism with parathyroid carcinomas: Clinical and molecular features. Clin Endocrinol (Oxf) 48: 6772.
  • 35
    Dionisio P, Stramignoni E, Passarino G, Pucci A, Valenti M, Berto IM, Portigliatti Barbos M, Cadario A, Gasparri G, Bajardi P 1996 Recurrent secondary hyperparathyroidism due to parathyroid carcinoma: Usefulness of Ki-67 immunostaining in the diagnosis of a malignant parathyroid tumor. Nephron 74: 720723.
  • 36
    Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349: 17221729.
  • 37
    Zakian VA 1995 Telomeres: Beginning to understand the end. Science 270: 16011607.
  • 38
    Urquidi V, Tarin D, Goodison S 2000 Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 51: 6579.
  • 39
    Fu W, Begley JG, Killen MW, Mattson MP 1999 Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 274: 72647271.
  • 40
    Nugent CI, Bosco G, Ross LO, Evans SK, Salinger AP, Moore JK, Haber JE, Lundblad V 1998 Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr Biol 8: 657660.
  • 41
    Ishikawa T, Kamiyama M, Hisatomi H, Ichikawa Y, Momiyama N, Hamaguchi Y, Hasegawa S, Narita T, Shimada H 1999 Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells. Cancer Lett 141: 187194.
  • 42
    Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL 2003 Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 63: 579585.
  • 43
    Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, Jackson GG, Durack DT, Andrews JC, Nusinoff-Lehrman S, Barry DW, and the AZT Collaborative Working Group 1989 Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA 262: 24052410.
  • 44
    Furman PA, Painter GR, Anderson KS 2000 An analysis of the catalytic cycle of HIV-1 reverse transcriptase: Opportunities for chemotherapeutic intervention based on enzyme inhibition. Curr Pharm Des 6: 547567.
  • 45
    Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW 1986 Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 83338337.
  • 46
    Strahl C, Blackburn EH 1996 Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 5365.
  • 47
    Murakami J, Nagai N, Shigemasa K, Ohama K 1999 Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 35: 10271034.
  • 48
    Andreuccetti M, Allegrini G, Antonuzzo A, Malvaldi G, Conte PF, Danesi R, Del Tacca M, Falcone A 1996 Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: In vitro synergistic cytotoxicity and DNA-induced strand-breaks. Eur J Cancer 32A: 12191226.
  • 49
    Yasuda C, Kato M, Kuroda D, Ohyanagi H 1997 Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3′-azido-3′-deoxythymidine for the gastric cancer cell line MKN28 in vivo. Jpn J Cancer Res 88: 97102.
  • 50
    Wagner CR, Ballato G, Akanni AO, McIntee EJ, Larson RS, Chang S, Abul-Hajj YJ 1997 Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res 57: 23412345.
  • 51
    Wit FW, Sol CJ, Renwick N, Roos MT, Pals ST, van Leeuwen R, Goudsmit J, Reiss P 1998 Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 12: 218219.
  • 52
    Tosi P, Gherlinzoni F, Visani G, Coronado O, Costigliola P, Mazzetti M, Gritti F, Chiodo F 1998 AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas. Leuk Lymphoma 30: 175179.
  • 53
    Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, Nethersell AB, Conte PF 1996 Intravenous azidothymidine with fluorouracil and leucovorin: A phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 14: 729736.
  • 54
    Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM 1995 Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332: 17441748.
  • 55
    Peacock M 2002 Normalization of hypercalcemia with the calcimimetic AMG 073 in a patient with metastatic parathyroid cancer. J Bone Miner Res 17: S1: 381.
  • 56
    Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, McCary LC, Olson KA, Turner SA, Peacock M 2003 The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. J Bone Miner Res 18: S2: S171.
  • 57
    Rubin M, Sliney J, McCary LC, Silverberg SJ, Bilezikian JP 2003 Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCl in patients with parathyroid carcinoma. J Bone Miner Res 18: S2: S392.